Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Impact in
- Oncology 398
Classified as
- Journal
- PubMed
In The Last Decade
doi.org/w10235037 →Countries where authors are citing Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
This map shows the geographic impact of Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. more than expected).
Fields of papers citing Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
This network shows the impact of Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action..
About Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
This paper, published in 2002, received 506 indexed citations . Written by F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Walter King, Steven Seelig and Carlos L. Arteaga covering the research area of Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. It is primarily cited by scholars working on Oncology (398 citations), Radiology, Nuclear Medicine and Imaging (263 citations), Molecular Biology (251 citations), Pulmonary and Respiratory Medicine (50 citations) and Immunology and Allergy (44 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w10235037.